MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-13-2026
Milestone Pharmaceuticals Deferred Revenue 2011-2026 | MIST
Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.Features of the metric
- Sources of future cash inflows
A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability. - Assessment of operational stability
Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages. - Risks and obligations
Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results. - Analysis of liquidity and cash flow
Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks. - Impact on company valuation
In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).
Quarterly Deferred Revenue Milestone Pharmaceuticals
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 416 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 416 K | 416 K | 416 K |
Deferred Revenue of other stocks in the Biotechnology industry
| Issuer | Deferred Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
86.5 M | - | 2.43 % | $ 254 M |  Germany |
 |
Coherus BioSciences
CHRS
|
1.96 M | $ 1.57 | -3.68 % | $ 184 M |  USA |
 |
Amphastar Pharmaceuticals
AMPH
|
643 K | $ 16.87 | -2.49 % | $ 789 M | USA |
 |
AgeX Therapeutics
AGE
|
283 K | - | -10.17 % | $ 12.2 K | USA |
 |
I-Mab
IMAB
|
563 K | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
15.9 M | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
124 K | - | 2.54 % | $ 160 B |  France |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.69 M | - | -1.52 % | $ 24.7 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
8.25 M | $ 7.47 | -4.6 % | $ 205 M |  Israel |
 |
Exelixis
EXEL
|
1.12 M | $ 50.13 | -1.9 % | $ 13.6 B | USA |
 |
Fortress Biotech
FBIO
|
728 K | $ 2.41 | 4.78 % | $ 67.2 M | USA |
 |
Midatech Pharma plc
MTP
|
1.3 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
AbCellera Biologics
ABCL
|
13.5 M | $ 4.09 | -7.05 % | $ 1.22 B |  Canada |
 |
Autolus Therapeutics plc
AUTL
|
3.5 M | $ 1.63 | 2.52 % | $ 434 M | Britain |
 |
BioNTech SE
BNTX
|
300 M | $ 89.55 | -2.65 % | $ 21.6 B | Germany |
 |
Galectin Therapeutics
GALT
|
200 K | $ 2.17 | -7.66 % | $ 139 M | USA |
 |
Celyad Oncology SA
CYAD
|
2.21 M | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
9.09 M | - | -7.31 % | $ 87 M | USA |
 |
Generation Bio Co.
GBIO
|
10.6 M | - | - | $ 344 M | USA |
 |
IMV
IMV
|
139 K | - | - | $ 13.1 M | Canada |
 |
Gilead Sciences
GILD
|
202 M | $ 129.58 | -1.88 % | $ 161 B | USA |
 |
Advaxis
ADXS
|
165 K | - | -9.65 % | $ 45.9 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
405 K | $ 3.36 | -3.72 % | $ 5.53 M | Israel |
 |
Aeterna Zentaris
AEZS
|
2.19 M | - | 5.93 % | $ 314 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
517 K | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
158 M | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
6.3 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
957 K | - | 1.93 % | $ 17.4 M | USA |
 |
Esperion Therapeutics
ESPR
|
34.5 M | $ 3.12 | - | $ 649 M | USA |
 |
Genmab A/S
GMAB
|
26 M | $ 26.54 | -1.34 % | $ 1.72 B |  Danmark |
 |
AlloVir
ALVR
|
2.66 M | - | 4.14 % | $ 49.1 M | USA |